XERIS BIOPHARMA HOLDINGS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $30.00M, a 11.42% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $26.93M, a 32.43% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $2.89M.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $18.78M.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2022 was $30.00M, a 11.42% increase from fiscal 2021.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2021 was $26.93M, a 56.23% decline from fiscal 2020.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2020 was $61.51M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $30.00M 10-K · filed 2025-03-06 | |
| 2022-03-31 | $30.00M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $26.93M 10-K · filed 2024-03-06 | |
| 2021-03-31 | $26.93M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $61.51M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $2.89M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $18.78M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $39.84M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |